(2- (6- fluoro- 1H- indol- 3- yl)- ethyl)- (3- (2,2,3,3- tetrafluoropropoxy)benzyl)amine

11/01/2019 - "We included RCTs of idalopirdine for patients with AD and used Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) scores as a primary measure. "
11/01/2019 - "The efficacy and tolerability of idalopirdine, a selective 5-hydroxytryptamine6 receptor antagonist, in patients with Alzheimer's disease (AD) is uncertain. "
11/01/2019 - "Efficacy and safety of idalopirdine for Alzheimer's disease: a systematic review and meta-analysis."
01/01/2018 - "Lack of Benefit With Idalopirdine for Alzheimer Disease: Another Therapeutic Failure in a Complex Disease Process."
01/01/2015 - "Idalopirdine as a treatment for Alzheimer's disease."

12/01/2015 - "Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity."
01/01/2018 - "The obtained results indicate that idalopirdine reduces caloric intake and could be considered for further tests as a potential treatment of obesity."
01/01/2018 - "Idalopirdine significantly reduced caloric intake and prevented the development of obesity in tested animals. "
01/01/2018 - "It has been suggested that the blockade of 5-HT6 receptors may reduce food intake, and since idalopirdine is a clinically tested, selective 5HT6 receptor antagonist, it was chosen to be examined in animal models of obesity. "
12/01/2015 - "LuAE58054, at 5 mg kg(-1)/day i.p., was significantly anorectic in this model of obesity. "

12/01/2015 - "The present study clearly demonstrates the effectiveness of LuAE58054 in reducing body weight. "
01/01/2018 - "Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating."

01/01/2020 - "Correction to: Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease."
06/01/2019 - "Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease."
01/01/2017 - "Reducing falls in Parkinson's disease: interactions between donepezil and the 5-HT6 receptor antagonist idalopirdine on falls in a rat model of impaired cognitive control of complex movements."

09/01/2010 - "The results indicate that Lu AE58054 is a selective antagonist of 5-HT(6)Rs with good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia. "
09/01/2010 - "Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats."
09/01/2010 - "Lu AE58054 may be useful for the pharmacotherapy of cognitive dysfunction in disease states such as schizophrenia and Alzheimer's disease."
09/01/2010 - "Orally administered Lu AE58054 potently inhibited striatal in-vivo binding of the 5-HT(6) antagonist radioligand [(3)H]Lu AE60157 ([(3)H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline), with an ED(50) of 2.7 mg/kg. Steady-state modelling of an acute pharmacokinetic/5-HT(6)R occupancy time-course experiment indicated a plasma EC(50) value of 20 ng/ml. Administration of Lu AE58054 in a dose range (5-20 mg/kg p.o.) leading to above 65% striatal 5-HT(6)R binding occupancy in vivo, reversed cognitive impairment in a rat novel object recognition task induced after subchronic treatment for 7 d with phencyclidine (PCP 2 mg/kg b.i.d., i.p. "
01/01/2020 - "Among small molecules, most of them that are present in the last phases act as specific antagonists (Suvorexant, Idalopirdine, Intepirdine, Trazodone, Carvedilol, and Risperidone) or agonists (Dextromethorphan, Resveratrol, Brexpiprazole) and frequently ameliorate cognitive dysfunctions. "